Articles - 1t74 mentioned but not cited (2)
- Recognition and accommodation at the androgen receptor coactivator binding interface. Hur E, Pfaff SJ, Payne ES, Grøn H, Buehrer BM, Fletterick RJ. PLoS Biol 2 E274 (2004)
- "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer. Caboni L, Kinsella GK, Blanco F, Fayne D, Jagoe WN, Carr M, Williams DC, Meegan MJ, Lloyd DG. J Med Chem 55 1635-1644 (2012)
Reviews citing this publication (30)
- Androgen receptor: structure, role in prostate cancer and drug discovery. Tan MH, Li J, Xu HE, Melcher K, Yong EL. Acta Pharmacol Sin 36 3-23 (2015)
- Chemistry and structural biology of androgen receptor. Gao W, Bohl CE, Dalton JT. Chem Rev 105 3352-3370 (2005)
- Alternatively spliced androgen receptor variants. Dehm SM, Tindall DJ. Endocr Relat Cancer 18 R183-96 (2011)
- Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Huang P, Chandra V, Rastinejad F. Annu Rev Physiol 72 247-272 (2010)
- Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Oncogene 33 2815-2825 (2014)
- The structures of type I polyketide synthases. Keatinge-Clay AT. Nat Prod Rep 29 1050-1073 (2012)
- RBR E3 ubiquitin ligases: new structures, new insights, new questions. Spratt DE, Walden H, Shaw GS. Biochem J 458 421-437 (2014)
- Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A. Nucl Recept Signal 6 e008 (2008)
- Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Sadar MD. Cancer Res 71 1208-1213 (2011)
- Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Lavery DN, McEwan IJ. Biochem J 391 449-464 (2005)
- Posttranslational modification of the androgen receptor in prostate cancer. van der Steen T, Tindall DJ, Huang H. Int J Mol Sci 14 14833-14859 (2013)
- Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Kumar R, McEwan IJ. Endocr Rev 33 271-299 (2012)
- Androgen receptor coregulators: recruitment via the coactivator binding groove. van de Wijngaart DJ, Dubbink HJ, van Royen ME, Trapman J, Jenster G. Mol Cell Endocrinol 352 57-69 (2012)
- Androgen receptor-cofactor interactions as targets for new drug discovery. Chang CY, McDonnell DP. Trends Pharmacol Sci 26 225-228 (2005)
- Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. McEwan IJ, Lavery D, Fischer K, Watt K. Nucl Recept Signal 5 e001 (2007)
- Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. Caboni L, Lloyd DG. Med Res Rev 33 1081-1118 (2013)
- Androgen receptor as a therapeutic target for androgen independent prostate cancer. Sharifi N, Farrar WL. Am J Ther 13 166-170 (2006)
- Modeling of Disordered Protein Structures Using Monte Carlo Simulations and Knowledge-Based Statistical Force Fields. Ciemny MP, Badaczewska-Dawid AE, Pikuzinska M, Kolinski A, Kmiecik S. Int J Mol Sci 20 E606 (2019)
- Androgen receptor as a therapeutic target. Gao W. Adv Drug Deliv Rev 62 1277-1284 (2010)
- Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations. Bryce AH, Antonarakis ES. Int J Urol 23 646-653 (2016)
- Coactivator recruitment of AhR/ARNT1. Endler A, Chen L, Shibasaki F. Int J Mol Sci 15 11100-11110 (2014)
- Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery. Sakkiah S, Ng HW, Tong W, Hong H. Expert Opin Ther Targets 20 1267-1282 (2016)
- Steroid receptor/coactivator binding inhibitors: An update. Skowron KJ, Booker K, Cheng C, Creed S, David BP, Lazzara PR, Lian A, Siddiqui Z, Speltz TE, Moore TW. Mol Cell Endocrinol 493 110471 (2019)
- Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. Asangani I, Blair IA, Van Duyne G, Hilser VJ, Moiseenkova-Bell V, Plymate S, Sprenger C, Wand AJ, Penning TM. J Biol Chem 296 100240 (2021)
- The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications. Cadwallader AB, Lim CS, Rollins DE, Botrè F. J Anal Toxicol 35 594-607 (2011)
- Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men. Robins DM. Mol Cell Endocrinol 352 26-33 (2012)
- The role of cofactors in sex steroid action. Trapman J, Dubbink HJ. Best Pract Res Clin Endocrinol Metab 21 403-414 (2007)
- Androgen and estrogen receptors: potential of crystallography in the fight against cancer. Nahoum V, Bourguet W. Int J Biochem Cell Biol 39 1280-1287 (2007)
- Androgen receptor modulators: a marriage of chemistry and biology. McEwan IJ. Future Med Chem 5 1109-1120 (2013)
- Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention. Dahiya UR, Heemers HV. Cells 11 936 (2022)
Articles citing this publication (76)
- Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Proc Natl Acad Sci U S A 102 6201-6206 (2005)
- A surface on the androgen receptor that allosterically regulates coactivator binding. Estébanez-Perpiñá E, Arnold LA, Nguyen P, Rodrigues ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, Guy RK, Webb P, Fletterick RJ. Proc Natl Acad Sci U S A 104 16074-16079 (2007)
- Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, Breton R. Protein Sci 15 987-999 (2006)
- Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. Askew EB, Gampe RT, Stanley TB, Faggart JL, Wilson EM. J Biol Chem 282 25801-25816 (2007)
- The role of androgen receptor mutations in prostate cancer progression. Brooke GN, Bevan CL. Curr Genomics 10 18-25 (2009)
- Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. J Biol Chem 280 37747-37754 (2005)
- Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Bai S, He B, Wilson EM. Mol Cell Biol 25 1238-1257 (2005)
- Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV. Nat Commun 4 1923 (2013)
- Compartmentalization of androgen receptor protein-protein interactions in living cells. van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, Dubbink HJ, Verschure PJ, Trapman J, Houtsmuller AB. J Cell Biol 177 63-72 (2007)
- Structural insights into the transcriptional and translational roles of Ebp1. Monie TP, Perrin AJ, Birtley JR, Sweeney TR, Karakasiliotis I, Chaudhry Y, Roberts LO, Matthews S, Goodfellow IG, Curry S. EMBO J 26 3936-3944 (2007)
- EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor. De Mol E, Fenwick RB, Phang CT, Buzón V, Szulc E, de la Fuente A, Escobedo A, García J, Bertoncini CW, Estébanez-Perpiñá E, McEwan IJ, Riera A, Salvatella X. ACS Chem Biol 11 2499-2505 (2016)
- Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery. Gentile F, Agrawal V, Hsing M, Ton AT, Ban F, Norinder U, Gleave ME, Cherkasov A. ACS Cent Sci 6 939-949 (2020)
- Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes. Yu X, Yi P, Hamilton RA, Shen H, Chen M, Foulds CE, Mancini MA, Ludtke SJ, Wang Z, O'Malley BW. Mol Cell 79 812-823.e4 (2020)
- Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. J Biol Chem 282 13648-13655 (2007)
- Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Duff J, McEwan IJ. Mol Endocrinol 19 2943-2954 (2005)
- Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J, Bevan CL. Oncogene 26 1757-1768 (2007)
- Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Brooke GN, Parker MG, Bevan CL. Oncogene 27 2941-2950 (2008)
- Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. Zhou XE, Suino-Powell KM, Li J, He Y, Mackeigan JP, Melcher K, Yong EL, Xu HE. J Biol Chem 285 9161-9171 (2010)
- Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R. Proc Natl Acad Sci U S A 104 11927-11932 (2007)
- Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Bai S, Wilson EM. Mol Cell Biol 28 1947-1963 (2008)
- Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. Gunther JR, Parent AA, Katzenellenbogen JA. ACS Chem Biol 4 435-440 (2009)
- Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. van de Wijngaart DJ, van Royen ME, Hersmus R, Pike AC, Houtsmuller AB, Jenster G, Trapman J, Dubbink HJ. J Biol Chem 281 19407-19416 (2006)
- Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Ni L, Llewellyn R, Kesler CT, Kelley JB, Spencer A, Snow CJ, Shank L, Paschal BM. Mol Cell Biol 33 4766-4778 (2013)
- Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Osguthorpe DJ, Hagler AT. Biochemistry 50 4105-4113 (2011)
- Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. Hodgson MC, Shen HC, Hollenberg AN, Balk SP. Mol Cancer Ther 7 3187-3194 (2008)
- Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. Gryder BE, Akbashev MJ, Rood MK, Raftery ED, Meyers WM, Dillard P, Khan S, Oyelere AK. ACS Chem Biol 8 2550-2560 (2013)
- Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. van de Wijngaart DJ, Molier M, Lusher SJ, Hersmus R, Jenster G, Trapman J, Dubbink HJ. J Biol Chem 285 5097-5105 (2010)
- Allosteric conversation in the androgen receptor ligand-binding domain surfaces. Grosdidier S, Carbó LR, Buzón V, Brooke G, Nguyen P, Baxter JD, Bevan C, Webb P, Estébanez-Perpiñá E, Fernández-Recio J. Mol Endocrinol 26 1078-1090 (2012)
- Development of an accurate classification system of proteins into structured and unstructured regions that uncovers novel structural domains: its application to human transcription factors. Fukuchi S, Homma K, Minezaki Y, Gojobori T, Nishikawa K. BMC Struct Biol 9 26 (2009)
- Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion. Karvonen U, Jänne OA, Palvimo JJ. Exp Cell Res 312 3165-3183 (2006)
- Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. Jehle K, Cato L, Neeb A, Muhle-Goll C, Jung N, Smith EW, Buzon V, Carbó LR, Estébanez-Perpiñá E, Schmitz K, Fruk L, Luy B, Chen Y, Cox MB, Bräse S, Brown M, Cato AC. J Biol Chem 289 8839-8851 (2014)
- Structural analysis of the evolution of steroid specificity in the mineralocorticoid and glucocorticoid receptors. Baker ME, Chandsawangbhuwana C, Ollikainen N. BMC Evol Biol 7 24 (2007)
- Communication between the ERRalpha homodimer interface and the PGC-1alpha binding surface via the helix 8-9 loop. Greschik H, Althage M, Flaig R, Sato Y, Chavant V, Peluso-Iltis C, Choulier L, Cronet P, Rochel N, Schüle R, Strömstedt PE, Moras D. J Biol Chem 283 20220-20230 (2008)
- Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression. van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Trapman J, Jenster G. Mol Endocrinol 23 1776-1786 (2009)
- Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis. Hsu CL, Liu JS, Wu PL, Guan HH, Chen YL, Lin AC, Ting HJ, Pang ST, Yeh SD, Ma WL, Chen CJ, Wu WG, Chang C. Mol Oncol 8 1575-1587 (2014)
- Cloning and expression analysis of androgen receptor gene in chicken embryogenesis. Katoh H, Ogino Y, Yamada G. FEBS Lett 580 1607-1615 (2006)
- Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif. Jin F, Claessens F, Fondell JD. J Biol Chem 287 858-870 (2012)
- Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SP. Nucleic Acids Res 45 3738-3751 (2017)
- Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. O'Mahony OA, Steinkamp MP, Albertelli MA, Brogley M, Rehman H, Robins DM. Mol Cancer Res 6 1691-1701 (2008)
- Hormone binding and co-regulator binding to the glucocorticoid receptor are allosterically coupled. Pfaff SJ, Fletterick RJ. J Biol Chem 285 15256-15267 (2010)
- In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby AC. Mol Endocrinol 26 1836-1846 (2012)
- Neofunctionalization of Androgen Receptor by Gain-of-Function Mutations in Teleost Fish Lineage. Ogino Y, Kuraku S, Ishibashi H, Miyakawa H, Sumiya E, Miyagawa S, Matsubara H, Yamada G, Baker ME, Iguchi T. Mol Biol Evol 33 228-244 (2016)
- A computational approach to evaluate the androgenic affinity of iprodione, procymidone, vinclozolin and their metabolites. Galli CL, Sensi C, Fumagalli A, Parravicini C, Marinovich M, Eberini I. PLoS One 9 e104822 (2014)
- Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression. Zhang F, Biswas M, Massah S, Lee J, Lingadahalli S, Wong S, Wells C, Foo J, Khan N, Morin H, Saxena N, Kung SHY, Sun B, Parra Nuñez AK, Sanchez C, Chan N, Ung L, Altıntaş UB, Bui JM, Wang Y, Fazli L, Oo HZ, Rennie PS, Lack NA, Cherkasov A, Gleave ME, Gsponer J, Lallous N. Nucleic Acids Res 51 99-116 (2023)
- Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. Lee JH, Isayeva T, Larson MR, Sawant A, Cha HR, Chanda D, Chesnokov IN, Ponnazhagan S. Proc Natl Acad Sci U S A 112 1392-1397 (2015)
- Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors. Petit-Topin I, Fay M, Resche-Rigon M, Ulmann A, Gainer E, Rafestin-Oblin ME, Fagart J. J Steroid Biochem Mol Biol 144 Pt B 427-435 (2014)
- Evolutionary identification of a subtype specific functional site in the ligand binding domain of steroid receptors. Raviscioni M, He Q, Salicru EM, Smith CL, Lichtarge O. Proteins 64 1046-1057 (2006)
- Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Buchanan G, Need EF, Barrett JM, Bianco-Miotto T, Thompson VC, Butler LM, Marshall VR, Tilley WD, Coetzee GA. Mol Cell Endocrinol 342 20-31 (2011)
- Ligand induced interaction of thyroid hormone receptor beta with its coregulators. Valadares NF, Polikarpov I, Garratt RC. J Steroid Biochem Mol Biol 112 205-212 (2008)
- Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator. Wilson EM. Endocrinology 148 1-3 (2007)
- A Model of Glucocorticoid Receptor Interaction With Coregulators Predicts Transcriptional Regulation of Target Genes. Monczor F, Chatzopoulou A, Zappia CD, Houtman R, Meijer OC, Fitzsimons CP. Front Pharmacol 10 214 (2019)
- Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells. Brooke GN, Gamble SC, Hough MA, Begum S, Dart DA, Odontiadis M, Powell SM, Fioretti FM, Bryan RA, Waxman J, Wait R, Bevan CL. Mol Cell Proteomics 14 1201-1216 (2015)
- Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection. van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Jenster G, Trapman J. Prostate 71 241-253 (2011)
- Molecular genetic studies in a case series of isolated hypoaldosteronism due to biosynthesis defects or aldosterone resistance. Turan I, Kotan LD, Tastan M, Gurbuz F, Topaloglu AK, Yuksel B. Clin Endocrinol (Oxf) 88 799-805 (2018)
- New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Godbole AM, Njar VC. Prostate Cancer 2011 918707 (2011)
- Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated Through Molecular Dynamics Simulations. Sakkiah S, Kusko R, Pan B, Guo W, Ge W, Tong W, Hong H. Front Pharmacol 9 492 (2018)
- Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT. Prostate 68 1570-1581 (2008)
- Similarities and differences between two modes of antagonism of the thyroid hormone receptor. Sadana P, Hwang JY, Attia RR, Arnold LA, Neale G, Guy RK. ACS Chem Biol 6 1096-1106 (2011)
- A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy. Chowdhury S, Beitel LK, Lumbroso R, Purisima EO, Paliouras M, Trifiro M. Horm Cancer 10 24-35 (2019)
- Androgen receptor gene mutations in androgen insensitivity syndrome cause distinct patterns of reduced activation of androgen-responsive promoter constructs. Werner R, Schütt J, Hannema S, Röpke A, Wieacker P, Hiort O, Holterhus PM. J Steroid Biochem Mol Biol 101 1-10 (2006)
- Computational design, synthesis, and evaluation of miniproteins as androgen receptor coactivator mimics. Vaz B, Möcklinghoff S, Folkertsma S, Lusher S, de Vlieg J, Brunsveld L. Chem Commun (Camb) 5377-5379 (2009)
- A multi-parameter imaging assay identifies different stages of ligand-induced androgen receptor activation. van Royen ME, van de Wijngaart DJ, Cunha SM, Trapman J, Houtsmuller AB. Cytometry A 83 806-817 (2013)
- Engineered repressors are potent inhibitors of androgen receptor activity. Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, Ali S, Bevan CL. Oncotarget 5 959-969 (2014)
- Modular type I polyketide synthase acyl carrier protein domains share a common N-terminally extended fold. Moretto L, Heylen R, Holroyd N, Vance S, Broadhurst RW. Sci Rep 9 2325 (2019)
- Perspectives on designs of antiandrogens for prostate cancer. Estébanez-Perpiñá E, Jouravel N, Fletterick RJ. Expert Opin Drug Discov 2 1341-1355 (2007)
- A fragment-based docking simulation for investigating peptide-protein bindings. Liao JM, Wang YT, Wang YT, Lin CS. Phys Chem Chem Phys 19 10436-10442 (2017)
- A structural mechanism of nuclear receptor biased agonism. Nemetchek MD, Chrisman IM, Rayl ML, Voss AH, Hughes TS. Proc Natl Acad Sci U S A 119 e2215333119 (2022)
- Field-based comparison of ligand and coactivator binding sites of nuclear receptors. Wohlfahrt G, Sipilä J, Pietilä LO. Biopolymers 91 884-894 (2009)
- Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site. Liu Y, Wu M, Wang T, Xie Y, Cui X, He L, He Y, Li X, Liu M, Hu L, Cen S, Zhou J. Front Pharmacol 9 1419 (2018)
- Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Hsu CL, Liu JS, Lin TW, Chang YH, Kuo YC, Lin AC, Ting HJ, Pang ST, Lee LY, Ma WL, Lin CC, Wu WG. Oncotarget 8 69508-69519 (2017)
- Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator. Poutiainen PK, Huhtala T, Jääskeläinen T, Petsalo A, Küblbeck J, Kaikkonen S, Palvimo JJ, Raunio H, Närvänen A, Peräkylä M, Juvonen RO, Honkakoski P, Laatikainen R, Pulkkinen JT. Mol Cell Endocrinol 387 8-18 (2014)
- Structural basis for computational screening of non-steroidal androgen receptor ligands. Nyrönen TH, Söderholm AA. Expert Opin Drug Discov 5 5-20 (2010)
- Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor. Fancher AT, Hua Y, Strock CJ, Johnston PA. Assay Drug Dev Technol 17 364-386 (2019)
- Lead evaluation of tetrahydroquinolines as nonsteroidal selective androgen receptor modulators for the treatment of osteoporosis. Nagata N, Furuya K, Oguro N, Nishiyama D, Kawai K, Yamamoto N, Ohyabu Y, Satsukawa M, Miyakawa M. ChemMedChem 9 197-206 (2014)
- Recovering Actives in Multi-Antitarget and Target Design of Analogs of the Myosin II Inhibitor Blebbistatin. Roman BI, Guedes RC, Stevens CV, García-Sosa AT. Front Chem 6 179 (2018)
- A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations. Doamekpor SK, Peng P, Xu R, Ma L, Tong Y, Tong L. Acta Crystallogr F Struct Biol Commun 79 95-104 (2023)